Surufatinib + Camrelizumab PDAC Phase 3 initiation

Summary by AI BETAClose X

HUTCHMED has initiated the Phase III portion of its Phase II/III trial evaluating surufatinib in combination with camrelizumab, nab-paclitaxel, and gemcitabine for treatment-naïve metastatic pancreatic ductal adenocarcinoma in China, with the first patient dosed on December 30, 2025. The Phase II portion showed promising results, with the combination regimen demonstrating a median progression-free survival of 7.20 months compared to 5.52 months for the control arm, a 50.1% reduction in risk of progression or death, and improved objective response rates (67.7% vs 41.9%). The Phase III part aims to enroll approximately 400 additional patients, with overall survival as the primary endpoint.

Disclaimer*

UK 100

Latest directors dealings